- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Daiichi to market Sonus agent in Asia
Ultrasound contrast developerSonus Pharmaceuticals has licensed distribution rights for itsEchoGen intravascular agent to Daiichi Pharmaceutical of Japan.Under the agreement, Daiichi will market and distribute EchoGenin Japan and several other Asian
Ultrasound contrast developerSonus Pharmaceuticals has licensed distribution rights for itsEchoGen intravascular agent to Daiichi Pharmaceutical of Japan.Under the agreement, Daiichi will market and distribute EchoGenin Japan and several other Asian nations, Bothell, WA-based Sonusannounced last month.
Daiichi will guide clinical development of EchoGen and willmanage its registration with the Japanese Ministry of Health andWelfare. Sonus will receive milestone payments from Daiichi.
EchoGen is entering phase-two clinical trials in the U.S.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
